Standard treatment with pegylated interferon and ribavirin only cures just over half of patients with HCV infection. Pereira and Jacobson review the evidence on the efficacy and promise of several specifically targeted antiviral therapies, which, most likely in combination with interferon and ribavirin, may improve the success rate of HCV therapy.
- Arema A. Pereira
- Ira M. Jacobson